Neumora Therapeutics Announces Positive Preclinical Data for NMRA-215

Neumora Therapeutics, Inc. announced positive preclinical data for NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor. The data, derived from three diet-induced obesity (DIO) mouse studies, showed that NMRA-215 achieved class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction and 26% in combination with high doses of semaglutide. The company plans to initiate a Phase 1 clinical study in the first quarter of 2026. NMRA-215 is being developed for the treatment of cardiometabolic and neurodegenerative conditions, with potential applications in obesity and Parkinson’s disease. Neumora will present additional data during its virtual R&D day on October 27, 2025.